ArticleJournal of the National Cancer Institute2012

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

Paul D P Pharoah et al.PubMed ↗Publisher ↗

No numbers read from the abstract.